How GLP-1 direct-to-consumer programs are distorting utilization trends
Closed claims no longer reflect real-world GLP-1 treatment patterns GLP-1 utilization continues to...
When billed and allowed amounts aren’t enough: HealthVerity proprietary market cost offering in taXonomy
A better way to measure healthcare costs in closed claims data This is the second post in our four-part taXonomy X blog series (part 1 here), and here we’ll discuss one of the most common pain points in closed claims analytics: costs. Specifically,...
GLP-1 persistence: What semaglutide data reveals about patient behavior
As the new year begins, many patients refocus on weight management and long-term health goals. At...
AI trends shaping healthcare in 2026: agentic, physical & sovereign AI
Artificial intelligence is no longer something healthcare and life sciences teams are testing on...
How the FDA is using real-world evidence in safety and approval decisions
Regulatory decision-making depends on evidence that reflects how medical products perform in...
Understanding modern ulcerative colitis through real-world data
Industry trends in ulcerative colitis research: a new path Ulcerative colitis is a chronic...
Understanding re-identification risk in PPRL: key takeaways from our expert webinar
New research is challenging long-held assumptions about privacy-preserving record linkage (PPRL)....
Improving influenza decision making with multimodal vaccination and lab data
Early signals indicate continued declines in influenza vaccination uptake and shifts in the...
HCIC 2025: Data for smarter healthcare marketing
Our team had a great time at HCIC connecting with healthcare marketers, digital teams and consumer...
Accelerating real-world evidence with agentic AI
Real-world evidence (RWE) studies often stall on the same friction points: defining the most...
Veterans Day at HealthVerity: Two paths from service to impact
Veterans Day invites us to look beyond branch and rank to the people and stories behind the...